XIAP and neuroblastoma: To better understand the mechanisms by which these compounds target XIAP in high-risk neuroblastoma, binding interactions between the antagonists and XIAP were first determined in BE(2)-C and KELLY cells using a NanoBRET quantitative target engagement assay.